The randomized, double-blind, placebo-controlled trial aims to assess the safety, tolerability, and efficacy of intranasal foralumab in patients with na-SPMS, a form of multiple sclerosis (MS) ...
Tiziana Life Sciences (TLSA) announced dosing has commenced at Johns Hopkins University, JHU, Autoimmunity Center of Excellence, the third ...
Clinical Trials Arena on MSN8d
Tiziana Life Sciences begins dosing in trial of therapy for multiple sclerosisThe trial aims to evaluate the antibody’s efficacy in treating non-active secondary progressive multiple sclerosis.
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...
Tiziana Life Sciences (NASDAQ:TLSA) recently announced that it submitted its IND of fully human anti-CD3 monoclonal antibody foralumab to begin a phase 2 study for the treatment of patients with ...
[1],[2] Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of ...
Tiziana Life Sciences Ltd. NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback